HRTX Relative Valuation
HRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRTX is overvalued; if below, it's undervalued.
Historical Valuation
Heron Therapeutics Inc (HRTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.38 is considered Undervalued compared with the five-year average of -94.83. The fair price of Heron Therapeutics Inc (HRTX) is between 1.93 to 7.68 according to relative valuation methord. Compared to the current price of 1.26 USD , Heron Therapeutics Inc is Undervalued By 34.6%.
Relative Value
Fair Zone
1.93-7.68
Current Price：1.26
34.6%
Undervalued
-72.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Heron Therapeutics Inc. (HRTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.30. The thresholds are as follows: Strongly Undervalued below -16.56, Undervalued between -16.56 and -9.43, Fairly Valued between 4.83 and -9.43, Overvalued between 4.83 and 11.96, and Strongly Overvalued above 11.96. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
66.69
EV/EBIT
Heron Therapeutics Inc. (HRTX) has a current EV/EBIT of 66.69. The 5-year average EV/EBIT is -77.87. The thresholds are as follows: Strongly Undervalued below -1656.24, Undervalued between -1656.24 and -867.05, Fairly Valued between 711.32 and -867.05, Overvalued between 711.32 and 1500.51, and Strongly Overvalued above 1500.51. The current Forward EV/EBIT of 66.69 falls within the Historic Trend Line -Fairly Valued range.
1.38
PS
Heron Therapeutics Inc. (HRTX) has a current PS of 1.38. The 5-year average PS is 4.07. The thresholds are as follows: Strongly Undervalued below -3.75, Undervalued between -3.75 and 0.16, Fairly Valued between 7.98 and 0.16, Overvalued between 7.98 and 11.90, and Strongly Overvalued above 11.90. The current Forward PS of 1.38 falls within the Historic Trend Line -Fairly Valued range.
64.18
P/OCF
Heron Therapeutics Inc. (HRTX) has a current P/OCF of 64.18. The 5-year average P/OCF is -1.86. The thresholds are as follows: Strongly Undervalued below -55.88, Undervalued between -55.88 and -28.87, Fairly Valued between 25.15 and -28.87, Overvalued between 25.15 and 52.15, and Strongly Overvalued above 52.15. The current Forward P/OCF of 64.18 falls within the Strongly Overvalued range.
0.00
P/FCF
Heron Therapeutics Inc. (HRTX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.43. The thresholds are as follows: Strongly Undervalued below -32.97, Undervalued between -32.97 and -16.27, Fairly Valued between 17.12 and -16.27, Overvalued between 17.12 and 33.82, and Strongly Overvalued above 33.82. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Heron Therapeutics Inc (HRTX) has a current Price-to-Book (P/B) ratio of 32.89. Compared to its 3-year average P/B ratio of -3.41 , the current P/B ratio is approximately -1063.41% higher. Relative to its 5-year average P/B ratio of 0.88, the current P/B ratio is about 3617.13% higher. Heron Therapeutics Inc (HRTX) has a Forward Free Cash Flow (FCF) yield of approximately -13.48%. Compared to its 3-year average FCF yield of -28.60%, the current FCF yield is approximately -52.86% lower. Relative to its 5-year average FCF yield of -28.87% , the current FCF yield is about -53.30% lower.
32.89
P/B
Median3y
-3.41
Median5y
0.88
-13.48
FCF Yield
Median3y
-28.60
Median5y
-28.87
Competitors Valuation Multiple
The average P/S ratio for HRTX's competitors is 8.64, providing a benchmark for relative valuation. Heron Therapeutics Inc Corp (HRTX) exhibits a P/S ratio of 1.38, which is -84.04% above the industry average. Given its robust revenue growth of 16.47%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HRTX decreased by 25.88% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -14.78 to -45.78.
The secondary factor is the Revenue Growth, contributed 16.47%to the performance.
Overall, the performance of HRTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
TZOO
Travelzoo
6.69USD
-0.89%
LUNG
Pulmonx Corp
2.1USD
-4.98%
ATAI
Atai Beckley NV
3.97USD
-0.75%
DMAC
DiaMedica Therapeutics Inc
8.35USD
-1.65%
AENT
Alliance Entertainment Holding Corp
7.805USD
-0.76%
EIC
Eagle Point Income Company Inc
11.08USD
1.00%
NGNE
Neurogene Inc
18.68USD
-2.30%
CPSS
Consumer Portfolio Services Inc
9.23USD
2.10%
ZYXI
Zynex Inc
0.1418USD
-53.60%
Frequently Asked Questions
Is Heron Therapeutics Inc (HRTX) currently overvalued or undervalued?
Heron Therapeutics Inc (HRTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.38 is considered Undervalued compared with the five-year average of -94.83. The fair price of Heron Therapeutics Inc (HRTX) is between 1.93 to 7.68 according to relative valuation methord. Compared to the current price of 1.26 USD , Heron Therapeutics Inc is Undervalued By 34.60% .
What is Heron Therapeutics Inc (HRTX) fair value?
HRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Heron Therapeutics Inc (HRTX) is between 1.93 to 7.68 according to relative valuation methord.
How does HRTX's valuation metrics compare to the industry average?
The average P/S ratio for HRTX's competitors is 8.64, providing a benchmark for relative valuation. Heron Therapeutics Inc Corp (HRTX) exhibits a P/S ratio of 1.38, which is -84.04% above the industry average. Given its robust revenue growth of 16.47%, this premium appears unsustainable.
What is the current P/B ratio for Heron Therapeutics Inc (HRTX) as of Jan 08 2026?
As of Jan 08 2026, Heron Therapeutics Inc (HRTX) has a P/B ratio of 32.89. This indicates that the market values HRTX at 32.89 times its book value.
What is the current FCF Yield for Heron Therapeutics Inc (HRTX) as of Jan 08 2026?
As of Jan 08 2026, Heron Therapeutics Inc (HRTX) has a FCF Yield of -13.48%. This means that for every dollar of Heron Therapeutics Inc’s market capitalization, the company generates -13.48 cents in free cash flow.
What is the current Forward P/E ratio for Heron Therapeutics Inc (HRTX) as of Jan 08 2026?
As of Jan 08 2026, Heron Therapeutics Inc (HRTX) has a Forward P/E ratio of -72.00. This means the market is willing to pay $-72.00 for every dollar of Heron Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Heron Therapeutics Inc (HRTX) as of Jan 08 2026?
As of Jan 08 2026, Heron Therapeutics Inc (HRTX) has a Forward P/S ratio of 1.38. This means the market is valuing HRTX at $1.38 for every dollar of expected revenue over the next 12 months.